

Hepatitis C: Mavyret

1. Last Name:	Member Information		
Prescriber Information 1. Prescriber Name:	1.	Last Name: 2. First Name:	
1. Prescriber Name: 2. NPI #: 3. Requestor Name (Nurse/Office Staff): 4. Mailing Address: 5. Phone #: Ext. Fax #: Drug Information	3.	Trillium ID #: 5. Gender: 5. Gender:	
Drug Information 1. Drug Name: Mavyret	Pres	scriber Information	
Drug Information 1. Drug Name: Mavyret	1.	Prescriber Name: 2. NPI #:	
Drug Information 1. Drug Name: Mavyret	3.	Requestor Name (Nurse/Office Staff):	
Drug Information 1. Drug Name: Mavyret	4.	Mailing Address:	
1. Drug Name: Mavyret	5.	Phone #: Ext Fax #:	
Clinical Information Total Length of Therapy (Check ONE): □ 8 weeks = All genotypes: without cirrhosis or with compensated cirrhosis (Child Pugh-A) □ 12 weeks = Treatment naïve patients with a Liver or Kidney transplant recipients, or treatment-experienced patients with HCV Genotype 1 and previously treated with a regimen containing an NS3/4A Pl₂ without prior treatment with an NS5A inhibitor □ 16 weeks = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? □ Yes □ No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? □ Yes □ No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? □ Yes □ No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? □ Yes □ No HCV RNA (IU/mI): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? □ Yes □ No 6. Does the Member have an FDA labeled contraindications to Mavyret? □ Yes □ No 7. Is Marlet being used in combination with atazanavir and rifampin? □ Yes □ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? □ Yes □ No	Drug Information		
Clinical Information Total Length of Therapy (Check ONE): 8 weeks = All genotypes: without cirrhosis or with compensated cirrhosis (Child Pugh-A) 12 weeks = Treatment naïve patients with a Liver or Kidney transplant recipients, or treatment-experienced patients with HCV Genotype 1 and previously treated with a regimen containing an NS3/4A Pl ₂ without prior treatment with an NS5A inhibitor 16 weeks = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? Yes No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? Yes No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? Yes No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient) 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? Yes No HCV RNA (IU/ml): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? Yes No No No No No No No N	1.	Drug Name: Mavyret 2. Strength: 3. Quantity per 30 Days: 84	
Total Length of Therapy (Check ONE): □ 8 weeks = All genotypes: without cirrhosis or with compensated cirrhosis (Child Pugh-A) □ 12 weeks = Treatment naïve patients with a Liver or Kidney transplant recipients, or treatment-experienced patients with HCV Genotype 1 and previously treated with a regimen containing an NS3/4A Pl₂ without prior treatment with an NS5A inhibitor □ 16 weeks = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? □ Yes □ No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have icrirhosis? □ Yes □ No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? □ Yes □ No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient) 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? □ Yes □ No HCV RNA (IU/ml): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? □ Yes □ No 6. Does the Member have an FDA labeled contraindications to Mavyret? □ Yes □ No 7. Is Marlet being used in combination with atazanavir and rifampin? □ Yes □ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? □ Yes □ No	4.	Length of Therapy (in days): ☐ 8 Weeks ☐ 12 Weeks ☐ 16 Weeks	
□ 8 weeks = All genotypes: without cirrhosis or with compensated cirrhosis (Child Pugh-A) □ 12 weeks = Treatment naïve patients with a Liver or Kidney transplant recipients, or treatment-experienced patients with HCV Genotype 1 and previously treated with a regimen containing an NS3/4A Pl₂ without prior treatment with an NS5A inhibitor □ 16 weeks = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? □ Yes □ No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? □ Yes □ No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? □ Yes □ No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? □ Yes □ No HCV RNA (IU/ml): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? □ Yes □ No 6. Does the Member have an FDA labeled contraindications to Mavyret? □ Yes □ No 7. Is Marlet being used in combination with atazanavir and rifampin? □ Yes □ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? □ Yes □ No			
□ 12 weeks = Treatment naïve patients with a Liver or Kidney transplant recipients, or treatment-experienced patients with HCV Genotype 1 and previously treated with a regimen containing an NS3/4A PI₂ without prior treatment with an NS5A inhibitor □ 16 weeks = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? □ Yes □ No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? □ Yes □ No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? □ Yes □ No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? □ Yes □ No HCV RNA (IU/mI): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? □ Yes □ No 6. Does the Member have an FDA labeled contraindications to Mavyret? □ Yes □ No 7. Is Marlet being used in combination with atazanavir and rifampin? □ Yes □ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? □ Yes □ No			
patients with HCV Genotype 1 and previously treated with a regimen containing an NS3/4A Pl2 without prior treatment with an NS5A inhibitor 16 weeks = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? Yes No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? Yes No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? Yes No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? Yes No HCV RNA (IU/mI): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? Yes No 6. Does the Member have an FDA labeled contraindications to Mavyret? Yes No 7. Is Marlet being used in combination with atazanavir and rifampin? Yes No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? Yes No			
treatment with an NS5A inhibitor 16 weeks = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? Yes No Genotype is:		, , , , , , , , , , , , , , , , , , , ,	
□ 16 weeks = Recipients with an HCV Genotype 1 and previous treated with a regimen containing an NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? □ Yes □ No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? □ Yes □ No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? □ Yes □ No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? □ Yes □ No HCV RNA (IU/mI): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? □ Yes □ No 6. Does the Member have an FDA labeled contraindications to Mavyret? □ Yes □ No 7. Is Marlet being used in combination with atazanavir and rifampin? □ Yes □ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? □ Yes □ No	-		
without prior treatment with an NS3/4A protease inhibitor (including liver or kidney transplant recipients) or a recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? Yes No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? Yes No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? Yes No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? Yes No HCV RNA (IU/mI): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? Yes No 6. Does the Member have an FDA labeled contraindications to Mavyret? Yes No 7. Is Marlet being used in combination with atazanavir and rifampin? Yes No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? Yes No			
recipient with an HCV Genotype 3 and previously treated with a regimen containing PRS3 (including liver or kidney transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? Yes No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? Yes No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? Yes No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? Yes No HCV RNA (IU/ml): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? Yes No 6. Does the Member have an FDA labeled contraindications to Mavyret? Yes No 7. Is Marlet being used in combination with atazanavir and rifampin? Yes No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? Yes No		, , , , , , , , , , , , , , , , , , , ,	
transplant recipients). 1. Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6? Yes No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? Yes No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? Yes No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? Yes No HCV RNA (IU/mI): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? Yes No 6. Does the Member have an FDA labeled contraindications to Mavyret? Yes No 7. Is Marlet being used in combination with atazanavir and rifampin? Yes No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? Yes No			
 Is the member 3 years of age or older with a diagnosis of chronic hepatitis C (CHC) with genotype 1,2,3,4,5, or 6?			
 Yes □ No Genotype is: (documentation of genotype waived if treatment naïve patient) 2. Does the member have cirrhosis? □ Yes □ No Child-Pugh is: 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? □ Yes □ No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? □ Yes □ No HCV RNA (IU/ml): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? □ Yes □ No 6. Does the Member have an FDA labeled contraindications to Mavyret? □ Yes □ No 7. Is Marlet being used in combination with atazanavir and rifampin? □ Yes □ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? □ Yes □ No 			
 Does the member have cirrhosis?			
 3. Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted with this request? \(\text{Yes} \) No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? \(\text{Yes} \) No HCV RNA (IU/mI): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? \(\text{Yes} \) No 6. Does the Member have an FDA labeled contraindications to Mavyret? \(\text{Yes} \) No 7. Is Marlet being used in combination with atazanavir and rifampin? \(\text{Yes} \) No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? \(\text{Yes} \) No 		☐ Yes ☐ No Genotype is: (documentation of genotype waived if treatment naïve patient)	
with this request? \(\text{ Yes } \) No **Lab test results MUST be attached to the PA to be approved.** (documentation of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? \(\text{ Yes } \) No HCV RNA (IU/mI): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? \(\text{ Yes } \) No 6. Does the Member have an FDA labeled contraindications to Mavyret? \(\text{ Yes } \) No 7. Is Marlet being used in combination with atazanavir and rifampin? \(\text{ Yes } \) No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? \(\text{ Yes } \) No			
of genotype waived if treatment naïve patient 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? Yes No HCV RNA (IU/ml): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? Yes No 6. Does the Member have an FDA labeled contraindications to Mavyret? Yes No 7. Is Marlet being used in combination with atazanavir and rifampin? Yes No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? Yes No	3. /	Are medical records documenting the diagnosis of chronic hepatitis C with genotype and subtype being submitted	
 4. Does the member have a documented quantitative HCV RNA at baseline that was tested within the past 6 months (medical documentation required)? ☐ Yes ☐ No ☐ HCV RNA (IU/ml): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? ☐ Yes ☐ No 6. Does the Member have an FDA labeled contraindications to Mavyret? ☐ Yes ☐ No 7. Is Marlet being used in combination with atazanavir and rifampin? ☐ Yes ☐ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? ☐ Yes ☐ No 		•••	
(medical documentation required)? ☐ Yes ☐ No HCV RNA (IU/ml): and/or log10 value: 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? ☐ Yes ☐ No 6. Does the Member have an FDA labeled contraindications to Mavyret? ☐ Yes ☐ No 7. Is Marlet being used in combination with atazanavir and rifampin? ☐ Yes ☐ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? ☐ Yes ☐ No			
 5. As the provider, are you reasonably certain that treatment will improve the member's overall health status? ☐ Yes ☐ No 6. Does the Member have an FDA labeled contraindications to Mavyret? ☐ Yes ☐ No 7. Is Marlet being used in combination with atazanavir and rifampin? ☐ Yes ☐ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? ☐ Yes ☐ No 		·	
☐ Yes ☐ No 6. Does the Member have an FDA labeled contraindications to Mavyret? ☐ Yes ☐ No 7. Is Marlet being used in combination with atazanavir and rifampin? ☐ Yes ☐ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? ☐ Yes ☐ No			
 6. Does the Member have an FDA labeled contraindications to Mavyret? ☐ Yes ☐ No 7. Is Marlet being used in combination with atazanavir and rifampin? ☐ Yes ☐ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? ☐ Yes ☐ No 	5. <i>F</i>		
7. Is Marlet being used in combination with atazanavir and rifampin? ☐ Yes ☐ No 8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? ☐ Yes ☐ No			
8. Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? Yes No	6. [Does the Member have an FDA labeled contraindications to Mavyret? Yes No	
	7. I	Is Marlet being used in combination with atazanavir and rifampin? Yes No	
Signature of Prescriber: Date:	8. [Does the Member have moderate to severe hepatic impairment (Child-Pugh B or C)? ☐ Yes ☐ No	
Signature of Prescriber: Date:			
	Si	gnature of Prescriber: Date:	

(Prescriber Signature Mandatory)

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.